evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks

Proportion with zero bleeds · people without inhibitors

Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in proportion of participants with zero bleeds compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks

All adverse events · people without inhibitors

Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in all adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks

Serious adverse events · people without inhibitors

Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in serious adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Death or dependence (mRS 4 to 6) at day 90 · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in intracerebral haemorrhage expansion by 24 hours compared with placebo/open control (low certainty).

1 finding from 1 review

Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma

Death or dependence (mRS 4 to 6) at day 90 · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use

It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes death or dependence (mRS 4–6) compared with fresh frozen plasma (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma

Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use

It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes intracerebral haemorrhage expansion by 24 hours compared with fresh frozen plasma (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use

It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes all serious adverse events compared with fresh frozen plasma (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma

Death from any cause · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use

It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes death from any cause compared with fresh frozen plasma (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

All serious adverse events · adults with acute spontaneous intracerebral haemorrhage

It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control

Death from any cause · adults with acute spontaneous intracerebral haemorrhage

Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death from any cause compared with placebo/open control (moderate certainty).

1 finding from 1 review